Johnson & Johnson to Present New Data Spanning Vision Portfolio at ARVO 2026

JACKSONVILLE, FL - May 4, 2026 - Johnson & Johnson will present new data on several of its latest innovations spanning 17 posters and oral presentations, including the latest FDA-approved TECNIS PureSee IOL, at the 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting this week in Denver, CO.

"Across our vision portfolio, we're consistently generating scientific evidence to validate performance and guide innovation," said Caroline Blackie, VP of Global Medical Affairs, Vision, Johnson & Johnson. "With 40 million people in need of vision correction, that rigor helps us solve high unmet needs and expand what's possible for patients-supporting care from pediatric therapeutic solutions through the full range of advanced vision needs."

Key results from the company presentations include:

Image quality benefits of the TECNIS PureSee and TECNIS Odyssey IOLs

Pre-clinical testing showed that the image quality benefits of the TECNIS PureSee IOL remain largely consistent under real-world conditions, even when typical levels of lens tilt and decentration are present (about 5° and 0.25 mm). Additional testing further evaluated distance image quality for PC IOLs, including TECNIS Odyssey IOL, using natural images such as the moon.

· Pre-clinical assessment of combined tilt and decentration impact on performance of EDF IOLs. State, Mihai (Poster presentation: May 7, 2:00PM - 3:45PM MT)

· Evaluation of distance image quality in intraocular lenses using natural images. Alarcon Heredia, Aixa et al. (Oral presentation: May 6, 3:30PM - 3:45PM MT)

New insights link peripheral optics to functional vision

Optical bench testing and simulations showed that current standard IOLs provide similar peripheral refractive performance, regardless of manufacturer or lens type (including monofocal, multifocal, and extended-range-of-vision IOLs). The aberrations measured are higher in pseudophakic eyes than in phakic eyes. The data also showed that a potential new monofocal peripheral vision (PV) IOL^˄ design could improve peripheral performance to the level of a phakic eye while maintaining the same central vision as a monofocal control IOL, translating into real-world benefits such as faster reaction times and improved hazard detection while driving.

· In vitro evaluation and optical simulation of peripheral refractive errors in pseudophakic eyes. Romashchenko, Dmitry et al. (Poster presentation: May 7, 2:00PM - 3:45PM MT)

· New peripheral vision IOL: optical improvements to functional benefits. Del Aguila Carrasco, Antonio et al. (Poster presentation: May 7, 2:00PM - 3:45PM MT)

· Measurement of Peripheral Refractive Errors (PRE) in Pseudophakic Eyes with different IOL technologies comparing an autorefractor with an aberrometer. Barcala Gosende, Xoana et al. (Poster presentation: May 7, 2:00PM - 3:45PM MT)

· Relevance of Peripheral Vision and Reaction Time on Driving Performance. El Aissati, Sara et al. (Poster presentation: May 4, 11:15AM - 1:00PM MT)

A new moisture index to support correlations between evaporative water-loss resistance and contact lens materials that can influence on-eye performance

This research introduces a new method to compare soft contact lens materials based on how well they retain moisture. The method measures how much a lens slows water evaporation compared with saline alone (no lens) under controlled conditions at 40% relative humidity. Moisture retention is reported on a 0-100% scale. Across 20 commercially available contact lens materials, including ACUVUE and others, moisture retention values ranged from 6% to 72%, with differences noted by lens type (hydrogel vs. silicone hydrogel) and other material factors.

· Development of a Moisture Retention Index for Contact Lens Materials. Riederer, Donald et al. (Poster presentation: May 4, 11:15AM - 1:00PM MT)

New myopia research highlights sustained 24-month outcomes with ACUVUE Abiliti 1-Day^≠

Featured research includes 24-month myopia progression data in children wearing Abiliti 1-Day^≠ lenses, showing numerically less progression compared with a real-world control group. Additional studies include optical simulations evaluating on-eye image quality for non-coaxial and dual-focus lens designs, as well as a systematic review of soft contact lens safety in children. That review found lower rates of corneal infiltrative events in children aged 12 and under-the primary target age group for myopia control-compared with adults.

· 24-Month Myopia Progression for Chinese Children Wearing Abiliti™ 1-Day Contact Lenses and a Real-World Control. Nixon, Alex et al. (Poster presentation: May 3, 3:15PM - 5:00PM MT)

· Simulating the on-eye optical properties of two myopia control lens designs. Chen, Minghan et al. (Poster presentation: May 6, 2:00PM - 3:45PM MT)

· The Safety of Soft Contact Lens Wear in Children - A Systematic Review. Nti, Augustine et al. (Poster presentation: May 4, 11:15AM - 1:00PM MT)

In addition, Johnson & Johnson will share 8 presentations, which include research in geographic atrophy, featuring real-world evidence and patient preference data.

More poster and oral presentations from Johnson & Johnson at the ARVO 2026 Annual Meeting can be found through the event Online Meeting Planner.

^IOL not approved by the U.S. Food and Drug Administration (FDA).

≠This product is commercially available in select markets outside the U.S. It has not been approved by the U.S. Food and Drug Administration (FDA). Safety and effectiveness for U.S. use have not been established, and the product is not available for sale in the U.S.

Important Safety Information
ACUVUE^® Contact Lenses are indicated for vision correction. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Lenses should not be prescribed if patients have any eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. Consult the package insert for complete information. Complete information is also available from Johnson & Johnson Vision Care, Inc. by calling 1-800-843-2020, or by visiting www.jnjvisionpro.com.

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR TECNIS ODYSSEY™ IOL WITH
TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODEL DRN00V AND TECNIS ODYSSEY™ TORIC II IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODELS DRT150, DRT225, DRT300, DRT375

Rx Only

INDICATIONS:
The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ IOL, which is indicated for primary implantation for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The

TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ Toric II IOLs that are indicated for primary implantation for the visual correction of aphakia and for reduction of refractive astigmatism in adult patients with greater than or equal to 1 diopter of preoperative corneal astigmatism, in whom a cataractous lens has been removed. Compared to an aspheric monofocal lens, the TECNIS Odyssey™ IOLs mitigate the effects of presbyopia by providing improved visual acuity at intermediate and near distances to reduce eyeglass wear, while maintaining comparable distance visual acuity. The lens is intended for capsular bag placement only.

WARNINGS:
Intraocular lenses may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition or may pose an unreasonable risk to the eyesight of patients. Patients should have well-defined visual needs and be informed of possible visual effects (such as a perception of halo, starburst or glare around lights), which may be expected in nighttime or poor visibility conditions. Patients may perceive these visual effects as bothersome, which, on rare occasions, may be significant enough for the patient to request removal of the IOL. The physician should carefully weigh the potential risks and benefits for each patient. Patients with a predicted postoperative residual astigmatism greater than 1.0 diopter, with or without a toric lens, may not fully benefit in terms of reducing spectacle wear. Rotation of the TECNIS Odyssey™ Toric II IOL from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible, prior to lens encapsulation. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes. Not doing so may result in the lens being stuck in the cartridge. Do not attempt to disassemble, modify, or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design.

PRECAUTIONS:
Interpret results with caution when using autorefractors or wavefront aberrometers that utilize infrared light, or when performing a duochrome test. Confirmation of refraction with maximum plus manifest refraction technique is strongly recommended. The ability to perform some eye treatments (e.g., retinal photocoagulation) may be affected by the IOL optical design. The surgeon should target emmetropia, as this lens is designed for optimum visual performance when emmetropia is achieved. The TECNIS Odyssey™ IOLs should not be placed in the ciliary sulcus. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case. Residual viscoelastic and/or over-inflation of the capsular bag may allow the lens to rotate, causing misalignment of the TECNIS Odyssey™ Toric II IOL. All preoperative surgical parameters are important when choosing a TECNIS Odyssey™ Toric II IOL for implantation, including preoperative keratometric cylinder (magnitude and axis), incision location, the surgeon's estimated surgically induced astigmatism (SIA) and biometry. Variability in any of the preoperative measurements can influence patient outcomes and the effectiveness of treating eyes with lower amounts of preoperative corneal astigmatism. The effectiveness of TECNIS Odyssey™ Toric II IOLs in reducing postoperative residual astigmatism in patients with preoperative corneal astigmatism < 1.0 diopter has not been demonstrated. Patients with a predicted postoperative astigmatism greater than 1.0 D may not be suitable candidates for implantation with the TECNIS Odyssey™ IOLs, as they may not obtain the benefits of reduced spectacle wear or improved intermediate and near vision seen in patients with lower predicted postoperative astigmatism.

ATTENTION:
Reference the Directions for Use for a complete listing of Indications and Important Safety Information.

INDICATIONS and IMPORTANT SAFETY INFORMATION for TECNIS PureSee™ IOL and TECNIS PureSee™ Toric II IOLs with TECNIS SIMPLICITY™ Delivery System

Rx Only

INDICATIONS FOR USE

The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS PureSee™ IOL, which is indicated for primary implantation for the visual correction of aphakia in adult patients with less than 1 diopter of pre-existing corneal astigmatism in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the TECNIS PureSee™ IOL provides improved intermediate visual acuity, while maintaining comparable distance visual acuity. The lens is intended for capsular bag placement only.

The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS PureSee™ Toric II IOLs, which are indicated for primary implantation for the visual correction of aphakia and for reduction of refractive astigmatism in adult patients with greater than or equal to 1 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed. The lenses mitigate the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the TECNIS PureSee™ Toric II IOLs provide improved intermediate visual acuity, while maintaining comparable distance visual acuity. The lenses are intended for capsular bag placement only.

WARNINGS
Physicians should weigh the potential benefit/risk ratio of IOL implantation in patients with any of the conditions listed in the Directions for Use, as intraocular lenses may exacerbate an existing condition or may pose an unreasonable risk to the eyesight of patients.

Rotation of the TECNIS PureSee™ Toric II IOLs away from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible prior to lens encapsulation.

Do not attempt to disassemble, modify or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design. Do not implant the lens if the rod tip does not advance the lens or if it is jammed in the delivery system. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes.

PRECAUTIONS
Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the benefit/risk ratio before implanting a lens in a patient. Potential risks for cataract surgery may include but are not limited to infection, inflammation, retinal detachment, increased eye pressure, hyphema, hypopyon, and posterior capsular opacification. Prior to surgery, the surgeon must inform prospective patients of the possible risks and benefits associated with the use of this device and provide a copy of the patient information brochure to the patient. Autorefractors may not provide optimal postoperative refraction of patients with the IOL. Manual refraction with maximum plus technique is strongly recommended. This is a single-use device. Do not resterilize the lens or the delivery system. Do not store the device in direct sunlight or at a temperature under 41°F (5°C) or over 95°F (35°C). Do not autoclave the delivery system. Do not use if the delivery system has been dropped or if any part was inadvertently struck while outside the shipping box. The sterility of the delivery system and/or the lens may have been compromised. The recommended temperature for implanting the lens is at least 63°F (17°C). Do not advance the lens unless ready for lens implantation. Do not leave the lens in a folded position more than 10 minutes. The use of balanced salt solution or ophthalmic viscosurgical devices (OVDs) is required when using the delivery system. The lens should be placed entirely in the capsular bag. The lens should not be placed in the ciliary sulcus.

ATTENTION:
Reference the Directions for Use for a complete listing of Indications and Important Safety Information.

About Vision at Johnson & Johnson
Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients' eyes. We have a bold ambition: Vision Made Possible - improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at clearvisionforyou.com, follow @JNJVision on Twitter, Johnson & Johnson | Vision on LinkedIn, and @JNJVision on Facebook.

About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://www.jnjmedtech.com/en-US/. Follow us at @JNJMedTech and on LinkedIn.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to TECNIS PureSee and TECNIS Odyssey IOLs and ACUVUE Abiliti 1-Day. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

© Johnson & Johnson and its affiliates 2026. All rights reserved.

2026PP09492

Media contact:
Jamie Hall
[email protected]